In‐vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein

Journal of Pharmacy and Pharmacology

Fecha de publicación: 29 April 2019

DOI: https://doi.org/10.1111/jphp.13100

Autores: Suqin Feng, Liang Zheng, Shiwei Tang, Juan Gu, Xuehua Jiang, Ling Wang.

Background: Antidepressants need to penetrate the blood–brain barrier (BBB) to exert their functions in the central nervous system. Breast cancer resistance protein (BCRP), an efflux transporter abundantly expressed in the BBB, prevents the accumulation of many drugs in the brain. This study aimed to identify whether five commonly used antidepressants (sertraline, duloxetine, fluoxetine, amitriptyline and mirtazapine) are BCRP substrates.